Cargando…
Silencing activating transcription factor 2 promotes the anticancer activity of sorafenib in hepatocellular carcinoma cells
The present study aimed to investigate the anticancer effect of sorafenib combined with silencing of activating transcription factor 2 (ATF2) in hepatocellular carcinoma (HCC) cells and to assess the underlying molecular mechanisms. Huh-7 HCC cell line was selected for the present study. Small inter...
| Autores principales: | , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
D.A. Spandidos
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5983979/ https://www.ncbi.nlm.nih.gov/pubmed/29693700 http://dx.doi.org/10.3892/mmr.2018.8921 |